



Dear EML Secretariat,

I am writing on behalf of the Coalition for Headache and Migraine Patients (CHAMP), a nonprofit organization dedicated to uniting the most influential patient advocacy organizations and leaders in the field of headache disease. We strongly support initiatives that advance access to effective treatments for the debilitating conditions headache and migraine patients face.

We have carefully reviewed the applications for the following therapies with great interest:

- [A.10 eletriptan naproxen, migraine
- A.13 fremanezumab, high frequency and chronic migraine
- I.2 amitriptyline - migraine prophylaxis
- I.3 bisoprolol - migraine prophylaxis
- I.7 Ibuprofen - acute migraine treatment
- I.10 Prednisolone, sumatriptan and verapamil - cluster headache]

These medications represent essential advancements in the treatment landscape for migraine and cluster headache, which remain significantly underdiagnosed and inadequately managed worldwide. The addition of these therapies would not only expand treatment options but also address critical gaps in care, ultimately improving the quality of life for millions of individuals who suffer from these disabling conditions.

As an organization deeply committed to advocating for equitable access to headache and migraine treatments, CHAMP fully supports these applications and stands ready to assist in furthering this effort. We welcome the opportunity to collaborate and provide any necessary expertise or resources to ensure these therapies become widely accessible. The approval of these treatments would mark a significant step forward in global neurological health and patient-centered care.

Sincerely,

Susan Doughty, Executive Director  
Coalition for Headache and Migraine Patients (CHAMP)